Efeito do Enalapril na função metabólica e inflamação hepática de camundongos obesos

Abstract

Obesity is a chronic disease caused by the association of multiple factors that result in excessive accumulation of body fat. It currently represents a major public health problem due to its epidemiological coverage and its association with other very prevalent problems, such as arterial hypertension and type 2 diabetes mellitus. The development of Metabolic Syndrome is also related to obesity, among other causes of an imbalance in the System Renin Angiotensin. The objective of this study was to analyze the effects of Enalapril on the metabolic function and hepatic inflammation of mice treated with high fat diet. The experiment was performed with 32 male Swiss mice (8 weeks old) equally and randomly divided into 4 groups (n = 8). The groups were divided into standard diet (DP), standard diet plus Enalapril (DH + ENAL), high fat diet (DH) and high fat diet plus Enalapril (DH + ENAL). Weekly measurements of animal weight and feed intake and glucose tolerance (TTG) and insulin sensitivity (TSI) measurements were performed and ultrasound was used for liver and epididymal fat pad evaluation, animals were sacrificed by decapitation and collected and stored blood and tissue samples. Liver samples were submitted to HE histology and gene expression analysis by RT-PCR. The statistical analysis was done in Graph Pad Prism Software and analyzed under 95% confidence (P <0.05). Data are expressed as the mean ± SD. Statistical significance of differences in mean values between groups was assessed by ANOVA or Test T factor. The results demonstrate a decrease in weight after treatment with Enalapril, as well as the size of epididymal adipose tissue (EAT) which was lower in the treated groups with the medicine. There was a tendency for a better glycemic profile in the treated groups, with lower fasting glucose and faster recovery to TTG and TSI. Hepatic echogenicity and steatosis measurement were lower in the groups receiving Enalapril. Gene expression revealed increased hepatic inflammation in animals receiving the medication.